The METEOR study: Frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs

International Clinical Psychopharmacology

Volumn 26, Issue 6, 2011, Pages 291-302

  Falissard, Bruno ^a   Mauri, Mauro ^d   Shaw, Ken ^e   Wetterling, Tilman ^f   Doble, Adam ^c   Giudicelli, Agnès ^b   De Hert, Marc ^g  

^a Universite Paris Sud   (France)

^b SANOFI   (France)

^c Foxymed   (France)

^d UNIVERSITY OF PISA   (Italy)

^e PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^f Vivantes Klinikum Hellersdorf   (Germany)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

antipsychotics; diabetes; metabolic disorders; prevalence; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TRIACYLGLYCEROL; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; INFORMATION PROCESSING; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; MULTICENTER STUDY; OBESITY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPENSITY SCORE; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; COMORBIDITY; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; EUROPE; FEMALE; HUMANS; HYPERTENSION; INTERVIEW, PSYCHOLOGICAL; MALE; METABOLIC DISEASES; MIDDLE AGED; OBESITY; PHARMACOEPIDEMIOLOGY; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME; TRIGLYCERIDES; WEIGHT GAIN; YOUNG ADULT;

EID: 80053604527     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834a5bf6     Document Type: Article

References (65)

1. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, 4th ed. Text Revision. Washington, DC: American Psychiatric Association.
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinology and North American Association for the study of obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601.
3. Andrews EA, Avorn J, Bortnichak EA, Chen R, Dai WS, Dieck GS, et al. (1996). Guidelines for good epidemiology practices for drug, device, and vaccine research in the United States. Pharmacoepidemiol Drug Saf 5:333-338. (Pubitemid 26395390)
4. Aranceta J, Perez Rodrigo C, Foz Sala M, Mentilla T, Serra Majem L, Moreno B, et al. (2004). Tables of coronary risk evaluation adapted to the Spanish population: the DORICA study. Med Clin (Barc). 123: pp. 686-691. (Pubitemid 40068835)
5. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP (2005). The prevalence of the metabolic syndrome using the national cholesterol educational program and international diabetes federation definitions. Curr Med Res Opin 21: 1157-1159. (Pubitemid 41140717)
6. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J (2007). Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 90:162-173. (Pubitemid 46177553)
7. Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR (2008). Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med 38:103-112.
8. Branca F, Nikogosian H, Lobstein T (2007). The challenge of obesity in the WHO European Region and the strategies for response. Copenhagen: World Health Organisation Regional Office for Europe.
9. Bresee LC, Majumdar SR, Patten SB, Johnson JA (2010). Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 117:75-82.
10. Bringer J, Fontaine P, Detournay B, Nachit-Ouinekh F, Brami G, Eschwege E (2009). Prevalence of diagnosed type 2 diabetes mellitus in the French general population: the INSTANT study. Diabetes Metab 35:25-31.
11. Casadebaig F, Philippe A, Guillaud-Bataille JM, Gausset MF, Quemada N, Terra JL (1997). Schizophrenic patients: physical health and access to somatic care. Eur Psychiatry 12:289-293. (Pubitemid 27433393)
12. Chien IC, Hsu JH, Lin CH, Bih SH, Chou YJ, Chou P (2009). Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr Res 111:17-22.
13. Cogneau J, Balkau B, Weill A, Liard F, Simon D (2006). Assessment of diabetes screening by general practitioners in France: the EPIDIA Study. Diabet Med 23:803-807. (Pubitemid 44366081)
14. Colton CW, Manderscheid RW (2006). Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 3:A42.
15. Correll CU (2007). Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr 12:35.
16. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, et al. (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 105:175-187.
17. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. (2006). Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2:14.
18. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. (2008). Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 101:295-303.
19. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ (2009). Cardiovascular disease and diabetes in people with severe mental illness position statement from the European psychiatric association (EPA), supported by the European association for the study of diabetes (EASD) and the European society of cardiology (ESC). Eur Psychiatry. 24: pp. 412-424.
20. De Hert M, Correll CU, Cohen D (2010a). Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 117:68-74.
21. De Hert M, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, et al. (2010b). The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology. Int J Methods Psychiatr Res 19:195-210.
22. de Leon J (2008). Beyond the 'hype' on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use. J Clin Psychopharmacol 28:125-131. (Pubitemid 351417116)
23. De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J (2007). Conference report: belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale 33:197-202. (Pubitemid 46787708)
24. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. (2000). Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903-912.
25. Duprez D, Van Helshoecht P, Van den Eynde W, Leeman M (2002). Prevalence of hypertension in the adult population of Belgium: report of a worksite study, attention hypertension. J Hum Hypertens 16:47-52. (Pubitemid 34134093)
26. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001). Executive summary of the third report of the national cholesterol education program (NCEP). JAMA 285:2486-2497.
27. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, et al. (2008). Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 69:514-519. (Pubitemid 351792324)
28. Gustiene O, Slapikas R, Klumbiene J, Sakalauskiene G, Kubilius R, Bagdzeviciute S, et al. (2005). The prevalence of metabolic syndrome in middle-aged in Kaunas population. Medicina (Kaunas) 41:867-876.
29. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R (2006). High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 21:93-98. (Pubitemid 43740316)
30. Henderson DC (2005). Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 66 (Suppl 6):11-20. (Pubitemid 41243257)
31. IMS Health. 2010 from http://www.imshealth.com.
32. International Diabetes Federation (2006). The diabetes atlas. 3rd edition Brussels: International Diabetes Federation.
33. Janssen PG, Gorter KJ, Stolk RP, Rutten GE (2007). Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study. Fam Pract 24:555-561.
34. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085-1097. (Pubitemid 351418005)
35. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. (2002). Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325:243.
36. Lamberti JS, Crilly JF, Maharaj K, Olson D, Wiener K, Dvorin S, et al. (2004). Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 65:702-706.
37. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009a). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41.
38. Leucht S, Kissling W, Davis JM (2009b). Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 39:1591-1602.
39. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223. (Pubitemid 41345943)
40. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32. (Pubitemid 41587460)
41. Melkersson K, Dahl ML (2004). Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64:701-723. (Pubitemid 38471372)
42. Meyer JM, Stahl SM (2009). The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 119:4-14.
43. Moebus S, Hanisch JU, Aidelsburger P, Bramlage P, Wasem J, Jockel KH (2007). Impact of 4 different definitions used for the assessment of the prevalence of the metabolic syndrome in primary healthcare: the german metabolic and cardiovascular risk project (GEMCAS). Cardiovasc Diabetol 6:22.
44. Morrato EH, Druss B, Hartung DM,Valuck RJ, Allen R, Campagna E, et al. (2010). Metabolic testing rates in 3 state medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 67:17-24.
45. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL (1996). Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68-73. (Pubitemid 26024880)
46. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86:15-22. (Pubitemid 44234064)
47. Novick D, Haro JM, Suarez D,Vieta E, Naber D (2009). Recovery in the outpatient setting: 36-month results from the schizophrenia outpatients health outcomes (SOHO) study. Schizophr Res 108:223-230.
48. Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000). Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 321:483-484. (Pubitemid 30623604)
49. Paton C, Esop R,Young C, Taylor D (2004). Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 110:299-305. (Pubitemid 39278989)
50. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225-233.
51. Schorr SG, Slooff CJ, Bruggeman R, Taxis K (2009). The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 43:1106-1111.
52. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-566. (Pubitemid 34274937)
53. Smith SM, Holohan J, McAuliffe A, Firth RG (2003). Irish diabetes detection programme in general practice. Diabet Med 20:717-722. (Pubitemid 41701464)
54. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K (2008). First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 192:406-411. (Pubitemid 351809892)
55. Taylor D, Young C, Esop R, Paton C, Walwyn R (2004). Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 185:152-156. (Pubitemid 39061459)
56. Taylor D, Young C, Mohamed R, Paton C, Walwyn R (2005). Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 19:182-186. (Pubitemid 40577223)
57. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620-627.
58. van Winkel R, De Hert M, Wampers M, Van Eyck D, Hanssens L, Scheen A, et al. (2008). Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry: e1-e8.
59. Weinmann S, Read J, Aderhold V (2009). Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 113:1-11.
60. Welborn TA, Reid CM, Marriott G (1997). Australian diabetes screening study: impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism 46:35-39.
61. Wetterling T (2001). Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24:59-73. (Pubitemid 32113367)
62. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998). Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847. (Pubitemid 28213628)
63. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. (1999). Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358-363. (Pubitemid 29289721)
64. Wolf HK, Tuomilehto J, Kuulasmaa K, Domarkiene S, Cepaitis Z, Molarius A, et al. (1997). Blood pressure levels in the 41 populations of the WHO MONICA Project. J Hum Hypertens 11:733-742. (Pubitemid 27503986)
65. Yood MU, DeLorenze G, Quesenberry CP Jr., Oliveria SA, Tsai AL, Willey VJ, et al. (2009). The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharma-coepidemiol Drug Saf 18:791-799.